All patients self-identified as non-White and nearly 69% of treated subjects had objectively measured Fitzpatrick skin types IV through VI The IL-23 inhibitor guselkumab demonstrated efficacy out to 100 weeks in the treatment of psoriasis across a spectrum of skin types, according to poster research presented at the 2026 annual meeting of the American Academy of Dermatology (AAD) in Denver. A full report will be published in the June 2026 issue of The Chronicle of Skin & Alle

There is just over one week until the 4th annual Colloquium on the Black Patient in Dermatology on Aug. 9, 2025, from 10:00 a.m. to 1:00...

Registration is open for the 10th annual Skin Spectrum Summit and the 4th annual Indigenous Skin Spectrum Summit, running together on...

Registration is open for the 10th annual Skin Spectrum Summit . The Summit is an educational congress of healthcare professionals...

Dr. Tashmeeta Ahad has been awarded the first Dr. Mercy Alexis Research Grant in Skin of Color Dermatology for her project on...

Phase III results presented during a late-breaking session at the annual meeting of the American Academy of Dermatology in San Diego,...